Abbott Followed FDA Rules On Humira Updates, Jury Hears

Law360, Chicago (May 3, 2013, 6:34 PM EDT) -- At an Illinois trial over claims that AbbVie Inc. and Abbott Laboratories failed to adequately warn about blockbuster arthritis drug Humira's risks, a regulatory expert testified Friday that Abbott had acted appropriately after the U.S. Food and Drug Administration told it to update information regarding the drug's link to infections.

David Feigal, an expert witness for the defense who has held positions at the FDA and pharmaceutical companies, said that he believed Abbott had complied with the FDA's rules and regulations regarding the risk evaluation and...
To view the full article, register now.